Edaravone is under clinical development by Grupo Ferrer Internacional and currently in Phase III for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase III drugs for Amyotrophic Lateral Sclerosis have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Edaravone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Edaravone overview

Edaravone is under development for the treatment of amyotrophic lateral sclerosis. It is administered as oral solution in the form of granules in sachet. The therapeutic candidate acts by targeting free radical.

Grupo Ferrer Internacional overview

Grupo Ferrer Internacional (Ferrer) is a provider of pharmaceuticals and chemicals. The company manufactures and markets pharmaceutical products for various therapeutic areas including cardiovascular, central nervous system, oncology, dermatology, gastrointestinal, phlebology, musculoskeletal system, pain, paediatrics and the respiratory system. It also provides over-the-counter medicines, dermo-cosmetics, food supplements, cough syrups and expectorants, anti-lice and insect repellent products, infant nutrition products, and other skincare products. Ferrer offers its products under Nucleo, Keltican, Nubit, Somazina, Ceraxon, Zynapse, Hidrasec, Tiorfan, Gelocatil, Abfentiq, and Kaptic brand names. The company also offers diagnostics services through its subsidiary Ferrer inCode. The company operates production facilities in Spain and the US. Ferrer is headquartered in Barcelona, Spain.

For a complete picture of Edaravone’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.